GW Pharmaceuticals PLC Sponsored ADR
Latest Trading on NASDAQ
$218.96
0.15%
(-0.32)
| Open | 219.31 |
|---|---|
| Previous Close | 219.28 |
| Today's Range |
218.60
219.54
|
| 52 Week Range |
87.07
219.57
|
| Volume | 1.46M |
| Avg. Volume (Weekly) | 743.32K |
| Bid | 0.00 |
|---|---|
| Ask | 0.00 |
| Market Cap | 6.86M |
| EPS | -1.81 |
| Shares Outstanding | 31.35K |
| YTD High | 219.57 |
Latest Trading on OTC
$17.00
16.92%
(+2.46)
| Open | 17.00 |
|---|---|
| Previous Close | 14.54 |
| Today's Range |
17.00
17.00
|
| 52 Week Range |
6.05
20.00
|
| Volume | 700.00 |
| Avg. Volume (Weekly) | 1.22K |
| Bid | 0.00 |
|---|---|
| Ask | 0.00 |
| Market Cap | 0.00 |
| EPS | 0.00 |
| Shares Outstanding | 0.00 |
| YTD High | 20.00 |
No data to display.
No data to display.
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.